A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
Dupilumab is now approved for bullous pemphigoid, showing efficacy in achieving sustained disease remission and reducing severity. The LIBERTY-BP ADEPT study demonstrated significant improvements in ...
Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...
Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...
Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...
The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results